Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Usage and effectiveness of Blinatumomab in treatment of relapsed/refractory philadelphia chromosome negative Acute Lymphoblastic Leukemia; A retrospective, observational study

Next Previous
Trial Profile

Usage and effectiveness of Blinatumomab in treatment of relapsed/refractory philadelphia chromosome negative Acute Lymphoblastic Leukemia; A retrospective, observational study

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms NEUF

Most Recent Events

  • 01 Apr 2022 Results (n=113) published in the Pediatric Blood and Cancer
  • 21 Jun 2020 Results of a cohort of paediatric patients (n=113) presented at the 25th Congress of the European Haematology Association.
  • 21 Jun 2020 Results (n=34) assessing patients characteristics, blinatumomab usage and effectiveness, presented at the 25th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top